KR20060078344A - Compositions for the herpes infection containing decursin and/or decursinol angelate, or angelica extract containing decursin and/or decursinol angelate - Google Patents

Abstract

The present invention relates to a composition for treating a herpes infection, comprising a decoxin and / or a decosinol angelate, or a Angelica extract comprising the decosin and / or decosinol angelate as an active ingredient.

The composition comprising the decancin and / or decosinol angelate of the present invention, or the Angelica extract comprising the decansin and / or decosinol angelate as an active ingredient, is a blister of herpes virus infection including herpes simplex and shingles. It has the effect of rapidly eliminating itching or pain, thus providing a safe and effective treatment for herpes infections without proper treatment.

Angelica Extract, Decusin, Decusinol Angelate, Herpes Infection

Description

COMPOSITIONS FOR THE HERPES INFECTION CONTAINING DECURSIN AND / OR DECURSINOL ANGELATE, OR ANGELICA EXTRACT CONTAINING DECURSIN AND / OR DECURSINOL ANGELATE}

The present invention relates to a composition for treating a herpes infection, comprising a decoxin and / or a decosinol angelate, or a Angelica extract comprising the decosin and / or decosinol angelate as an active ingredient.

Herpesviruses are DNA viruses belonging to relatively large sizes of 100 to 200 nm. Diseases caused by herpesvirus infection (or simply referred to as herpes) generally refer to herpes simplex (H. simplex) and shingles (H. zoaster).

Herpes simplex is caused by the herpes simplex virus (HSV).

As a disease, small blisters occur in one or two places of swelling, and small blisters occur around the lips and are often popped. It can occur not only around the lips but also on any part of the skin, and recurs in the same place.                         

Other forms of herpes simplex are genital, often recurrent genital herpes, considered a type of sexually transmitted disease.

Herpes zoster is caused by the varicella-zoster virus and is characterized by very pain, unlike herpes zoster. 1 to 2 weeks before the blisters develop, the area begins to hurt, and over time, small blisters form a cluster, and band-shaped blisters occur only on the skin where the strands are distributed.

The causative organism is varicella, which remains in the body of a person who has had chickenpox as a child, especially in elderly people, cancer patients with poor immune function, chronic wasting disease, and very tired people. The scab develops gradually and gradually improves, but pain remains even when blisters are lost, severe pain may continue for months or years, especially in elderly people with weakness, like neuralgia This is often the case, so early treatment is important.

If shingles occur along the facial nerve, facial nerve palsy may develop, and if it occurs in the eye, keratitis and severe vision may be lost. More common complications include pain from neuralgia for months to years. This is a continuing case, especially in elderly patients, which degrades the quality of life.

Herpes simplex relies on symptomatic therapy because no drug has been developed that can completely cure the virus. As early as possible, antiviral drugs are taken to reduce the severity and duration of the illness, and then antimicrobial or secondary antibiotics are used depending on the symptoms.

In the case of shingles, the treatment of injections of antiviral drugs for about one week within three to five days of blisters is standard.However, unlike herpes zoster, pain management is inevitable. Prevention is important above all. However, the pain may continue after the injection treatment in the case of late treatment, old age, cancer, AIDS, etc., and may last for more than a year in some cases.

As mentioned above, although herpes infection is caused by a virus, it is true that the effects of current antiviral agents are insufficient, and there is a fear of various complications or side effects. In the case of symptomatic therapy, the general treatment of skin blisters, itching, and pain has remained. Therefore, clinicians have been questioning whether they properly cope with the characteristic symptoms of herpes. Stronger pain management (such as narcotic analgesics) and the use of corticosteroids are being made, but as is well known, the side effects of these drugs are insignificant. In addition, antiviral agents such as acyclovir, which are used at the beginning, are known to exert almost all drugs through the kidneys to burden the kidneys, and have limited effects and various side effects of reluctant use of such drugs. Therefore, there is a need for a herpes infection for treating herpes infections, itching, pain, and less side effects.

Pharmacological action of decursin, decursinol angelate, decurcinol, and / or two or more species of Angelica gigas, which are the main components of Angelica gigas Nakai Many studies have been conducted on the disease, which is effective for leukemia cancer cells (Patent Publication No. 2001-0080265), for analgesic activity (Patent No. 10-0397950), for lung cancer, liver cancer, etc. (Patent registration notification) 10-0187881) and neuroprotective action (Patent Publication No. 2002-0078850).

However, pharmacologically or clinically identified therapeutic effects related to herpes infections with compositions using decansin and / or decusinol angelate, or Angelica extract, which are used as an active ingredient of decansin and / or decusinol angelate. There was no bar.

Therefore, the inventors of the present invention, if the therapeutic effect of herpes infection is confirmed in the decansin and / or decusinol angelate, or the Angelica extract using the same as an active ingredient, which has been widely used safely for a long time as a herbal medicine, The present inventors have determined that it is possible to provide a safe and widely available treatment for herpes infection.

In accordance with the above object, the present invention provides a composition for treating herpes infection, which comprises a Angelica extract containing Decasin represented by the following Chemical Formula 1 or Decasin represented by the following Chemical Formula 1 as an active ingredient.                     

(1)

(One)

In addition, the present invention provides a composition for treating herpes infection, which comprises a Angelica extract, which contains Decusinol Angelate or Decusinol Angelate represented by Formula 2 as an active ingredient.

(2)

(2)

In addition, the present invention provides a composition for treating herpes infection, which comprises the Angelica extract comprising the above-mentioned decusin and / or decusinol angelate, or as the active ingredient of decusin and / or decusinol angelate.

In addition, the composition of the present invention, the decansinol represented by the formula (3) to the sugar extracts containing the above-mentioned decusin and / or decusinol angelate, or decosin and / or decosinol angelate as an active ingredient It may further include the Angelica extract containing the decosinol.

(3)

(3)

The above-mentioned decusin, decosinol angelate or decosinol can be obtained by extracting, separating and purifying from Angelica gigas, and specific extraction and purification methods are described in the literature (Ji Ji-joon et al., Biochemical Society, 1, 25-32). (1970); and Korean J. Pharmacogn ., 21, 64-68 (1990)) and Patent Registration No. 10-2385092, but is not limited thereto, even if the solvent, extraction conditions, etc. are different Any extraction method can be used to obtain cine, decosinol angelate or decosinol.

The Angelica extract may further include all salts, organic salts, complexes, and the like, which are known to be incidental in the extraction process, in addition to the above-mentioned decusin, decosinol angelate or decosinol.

The above-mentioned decusin, decosinol angelate or decosinol can be synthesized and used as a specific method (Tetsuhiro Nemoto et al., Tetrahedron Letters , 41, 9569-9574 (2000); Lan Xie et al. J. Med) Chem ., 42, 2662-2672 (1999); Patent Application No. 2000-25749; and Patent Registration No. 10-0417624), but is not limited thereto, even if the synthesis conditions, such as the above decker Any synthetic method can be used to obtain cine, decosinol angelate or decosinol.

The decancin and / or decusinol angelate, or the Angelica extract containing decusin and / or decosinol angelate, exhibits a desirable effect on herpes simplex caused by herpes simplex virus infection.

The decancin and / or decusinol angelate, or the Angelica extract containing decusin and / or decosinol angelate, is preferred for shingles caused by varicella-zoster virus infection. Effect.                     

In the case of using the synthesized decusin, decosinol angelate or decosinol as the composition for treating herpes infection, all inorganic salts, organic salts, complexes, and the like, which are known to be involved in the synthesis of the raw materials, may be further included. Can be.

The above compounds are inorganic salts selected from the group consisting of sodium salts, potassium salts, magnesium salts, calcium salts or organic salts selected from the group containing lysine, ethanolamine, N, N'-dibenzylethylenediamine, It may be in the form of a pharmaceutically acceptable salt.

In addition, the present invention comprises a decancin and / or Decusinol Angelate, or a Angelica extract as the active ingredient of Decusin and / or Decusinol Angelate, and further comprises a pharmaceutically acceptable carrier or pharmaceutical additive Therapeutics for herpes infections are provided.

In the present invention, the treatment of herpes infection, which comprises a decancin and / or Decusinol Angelate, or a Angelica extract as the active ingredient of Decusin and / or Decusinol Angelate, and further comprises a pharmaceutically acceptable carrier An adjuvant therapeutic agent is provided.

Also in the present invention, herpes infection, which includes decancin and / or decusinol angelate, or Angelica extract as the active ingredient of decusin and / or decusinol angelate, further comprising a pharmaceutically acceptable food additive. A therapeutic supplement is provided.

The therapeutic composition for herpes infections comprising the decancin and / or the decosinol angelate, or the Angelica extract comprising the decansin and / or the decosinol angelate as an active ingredient, the target diseases, objectives and patients The dosage can be changed depending on the condition, and it is preferable to administer 1 to 100 mg, more preferably 3 to 30 mg, once a day, once or three times per 1 kg of body weight, usually as deckerin. In addition, the above dosage may be administered orally or parenterally formulated.

Hereinafter, the present invention will be described in more detail with reference to Examples. However, these examples do not limit the scope of the present invention.

Dosing method

A preparation comprising 300 mg of a deckerine and decusin angelate mixture obtained by culturing and extracting a domestic Angelica extract as described in Patent Registration No. 10-0385092 was prepared. The following clinical trials were performed by subjecting the following subjects to 1 to 2 times a day and 1 to 3 sachets once a day with drinking water of about 50 ml around 9 am and / or 8 pm every day.

Example 1

As shown in Table 1 below, 10 patients with herpes simplex or herpes zoster were checked for changes in blister / itch / pain while the composition of the present invention was administered for 1 week, and the results are shown in Table 1.                     

Table 1

Patient ID gender age Disease name water blister itch ache Comprehensive Evaluation One south 43 H.Simplex Lost on Day 2 Lost on Day 2 - Very effective 2 south 73 H.Simplex 3 days lost 3 days lost - Very effective 3 south 56 H.Simplex Lost on Day 2 Lost on Day 2 - Very effective 4 south 52 H.Simplex 3 days lost 3 days lost - Very effective 5 south 46 H.Simplex Lost on Day 2 Lost on Day 2 - Very effective 6 female 36 H.Simplex Lost on Day 2 Lost on Day 2 - Very effective 7 south 56 H.Simplex Lost on Day 2 Lost on Day 2 - Very effective 8 female 87 H.Zozter 3 days lost 3 days lost Day 3 relaxation Very effective 9 south 84 H.Zozter 3 days lost 3 days lost Day 3 relaxation Very effective 10 south 73 H.Zozter 3 days lost 3 days lost Day 3 relaxation Very effective

Among the 10 herpes simplex patients who received the composition of the present invention, blisters and itching disappeared within 2-3 days. In three patients with herpes zoster, the loss of blisters and itching was delayed slightly compared to patients with herpes simplex. On the third day, all cases were relieved and pain was alleviated within the same period. This is very encouraging considering that the patient was old and had suffered for a long time from shingles.

A total of 23 cases (11.7%) were reported in 21 of 196 patients with various syndromes receiving the composition of the present invention. In addition, adverse events such as cerebral nervous system side effects and urinary system side effects were reported, but in all cases, they were transient side effects, and there were no side effects that required discontinuation of experiments or continuous changes in clinical values.

Claims (14)

A composition for treating herpes infection, which comprises a decancin represented by the following formula (1) or a decansin represented by the following formula (1) as an active ingredient.

(One) A therapeutic composition for treating herpes infection, which comprises a Angelica extract containing Decusinol Angelate represented by the following Chemical Formula 2 or Decusinol Angelate represented by the following Chemical Formula 2.

(2) According to claim 1, Herpes infection composition for treating herpes, characterized in that it further comprises a decansinol angelate represented by the formula (2) or a decansinol angelate represented by the formula (2).

(2) The composition for treating herpes infection according to any one of claims 1 to 3, further comprising a Angelica extract containing decosinol represented by the following general formula (3) or decosinol represented by the following general formula (3): .

(3) The herpes infection therapeutic composition according to any one of claims 1 to 3, wherein the target disease of the herpes infection therapeutic composition is herpes simplex caused by herpes simplex virus infection. 4. The herpes infection therapeutic composition according to any one of claims 1 to 3, wherein the target disease of the herpes infection therapeutic composition is shingles caused by Veriella-Zoster virus infection. The method according to any one of claims 1 to 3, wherein the Angelica extract further comprises inorganic salts, organic salts and complexes which are known to be incidental to the extraction process in addition to decusin, decusinol angelate or decosinol. A herpes infection therapeutic composition, characterized in that. The method according to any one of claims 1 to 3, wherein the decusin and dekersinol angelate are synthesized, and further include inorganic salts, organic salts and complexes known to be incidental at the time of synthesis. Herpes infection therapeutic composition. The composition for treating herpes infection according to any one of claims 1 to 3, wherein the decusin and decosinol angelate are in the form of a pharmaceutically acceptable salt. 11. The composition of claim 10, wherein the salt is an inorganic salt selected from the group consisting of sodium salts, potassium salts, magnesium salts and calcium salts. 11. The composition of claim 10, wherein the salt is an organic salt selected from the group consisting of lysine, ethanolamine, and N, N'-dibenzylethylenediamine. Deucin and / or decusinol angelate, or a decancin and / or decansinol angelate extract containing the extract as an active ingredient, characterized in that it further comprises a pharmaceutically acceptable carrier or medicament additive Herpes Infection Therapeutic Compositions. An adjuvant treatment for herpes infection, which comprises decancin and / or decusinol angelate, or a Angelica extract comprising the decansin and / or decusinol angelate as an active ingredient, and further comprises a pharmaceutically acceptable carrier. Supplements for herpes infections, including decancin and / or decusinol angelate, or Angelica extract, which is an active ingredient of decusin and / or decusinol angelate, further comprising a pharmaceutically acceptable food additive .